Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of a shiny sun and gentle breeze passing by the quiet Pharmalot campus. Our shortest person is sleeping in today, since the local schoolhouse is closed for a needed break, and our other short one has left for the daily round of gainful employment. This leaves us to tend to the coffee kettle and usual task of foraging for interesting items. Speaking of which, here are a few. Hope your day is rewarding nd meaningful. And as always, do keep in touch. …

Gilead Sciences (GILD) will partner with privately held Insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drug maker tries to overcome its recent setback in developing NASH treatments, STAT writes. Insitro will receive $15 million, and up to $1 billion more down the line if it meets certain goals, and the deal — its first with a drug maker — offers a test of whether artificial intelligence can remake drug development. Last week, Gilead signed a deal with Novo Nordisk (NVO) to pursue a NASH treatment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy